1. Infection

Infection

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-146460
    Antimicrobial agent-2 2412592-33-5 99.38%
    Antimicrobial agent-2 (compound V-a) is a broad-spectrum antimicrobial agent, possessing inhibitory activity against various Gram-positive and -negative bacteria. Antimicrobial agent-2 has excellent inhibitory effect on Methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 1 μg/mL. Antimicrobial agent-2 can effectively damage the membrane and lead to the leakage of protein, also can induce the generation of ROS. Antimicrobial agent-2 exhibits low toxicity, no obvious resistance and good bioavailability.
    Antimicrobial agent-2
  • HY-150514
    ARN1468 1381459-14-8 99.34%
    ARN1468 (compound 5) is an orally active and potent serpins inhibitor. ARN1468 can inhibit serpins activity would set the protease free to further reduce prion accumulation. ARN1468 shows anti-prion effect in ScGT1 RML, ScGT1 22L, ScN2a RML, and ScN2a 22L cell lines, with EC50 values of 8.64, 19.3, 11.2, and 6.27 μM.
    ARN1468
  • HY-150734
    ODN 2007 455348-63-7
    ODN 2007, a class B CpG ODN (oligodeoxynucleotide), is a Toll-like receptor (TLR) ligand. ODN 2007 can be used as an immunomodulator, vaccine adjuvant, and enhance immune responses in mammals, fish, and humans. ODN 2007 sequence: 5'-TCGTCGTTGTCGTTTTGTCGTT-3'.
    ODN 2007
  • HY-150759
    HIV-1 inhibitor-45 2677762-43-3 99.54%
    HIV-1 inhibitor-45 (compound IA-6) is a potent HIV-1 RNase H inhibitor with an IC50 value of 0.067 μM. HIV-1 inhibitor-45 shows an antiviral activity.
    HIV-1 inhibitor-45
  • HY-150784
    XR8-89 2817811-16-6
    XR8-89 is a potent papain-like protease (PLpro) inhibitor with an IC50 value of 0.1 μM. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research.
    XR8-89
  • HY-151482
    SARS-CoV-2 Mpro-IN-2 2768834-39-3 98.96%
    SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent Mpro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies.
    SARS-CoV-2 Mpro-IN-2
  • HY-151561
    WM382 2606990-92-3 99.35%
    WM382 is an orally active and potent dual plasmepsin IX/X (PMIX/X) inhibitor with IC50 values of 1.4 nM and 0.03 nM, respectively. WM382 has robust in vivo efficacy at multiple stages of the malaria parasite life cycle and an excellent resistance profile.
    WM382
  • HY-153083
    COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
    COVID-19 Spike Protein mRNA will express COVID-19 spike protein, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design.
    COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
  • HY-158128
    MK-8527 1810869-23-8 99.02%
    MK-8527 is an orally active HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI) with antiviral activity. MK-8527 has a similar inhibitory mechanism to ISL (HY-104012).
    MK-8527
  • HY-158730
    N-3-Hydroxybutyryl-L-homoserine lactone 1325550-06-8 ≥98.0%
    N-3-Hydroxybutyryl-L-homoserine lactone (3-OH-C4-HSL) is an acyl-homoserine lactone, that can be isolated from Vibrionaceae. N-3-Hydroxybutyryl-L-homoserine lactone is a signaling molecule that is involved in bacterial quorum sensing (QS). N-3-Hydroxybutyryl-L-homoserine lactone senses the density of bacterial population, regulates the cellular process, such as bioluminescence, biofilm formation, and exo-enzyme production.
    N-3-Hydroxybutyryl-L-homoserine lactone
  • HY-161834
    RG100204 2140901-88-6 99.50%
    RG100204 is an orally active AQP9 inhibitor with anti-inflammatory activity. RG100204 can alleviate sepsis-induced cardiac dysfunction (both systolic and diastolic), improve renal dysfunction, and reduce the elevation of LDH, a marker of cellular injury.
    RG100204
  • HY-162066
    DNDI-6174 2868298-43-3
    DNDI-6174 is a cytochrome bc1 complex inhibitor with potent in vitro activity against a variety of Leishmania species. DNDI-6174 can reduce parasite burden in animal models of infection.
    DNDI-6174
  • HY-163462
    Poacic acid 160097-32-5
    Poacic Acid is a plant-derived stilbenoid with an antifungal activity. Poacic Acid localizes to the yeast cell wall and disrupts the production and assembly of β-1,3-glucan in the fungal cell walls. Poacic Acid exhibits fungicidal activity to Saccharomyces cerevisiae and plasma membrane-compromised Candida albicans mutants.
    Poacic acid
  • HY-17450A
    Aplaviroc hydrochloride 461023-63-2 99.94%
    Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.
    Aplaviroc hydrochloride
  • HY-A0147A
    Grepafloxacin hydrochloride 161967-81-3 99.23%
    Grepafloxacin (OPC-17116) hydrochloride is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia. Grepafloxacin hydrochloride has high tissue penetration and a promising pharmacodynamic profile.
    Grepafloxacin hydrochloride
  • HY-A0248B
    Polymyxin B2 34503-87-2
    Polymyxin B2 is a polypeptide antibiotic that has antibacterial activity, particularly against gram-negative bacteria. Polymyxin B2 kills the bacteria by binding to lipopolysaccharide molecules on the bacterial cell membrane, disrupting the integrity of the cell membrane and causing the cell contents to leak. Polymyxin B2 can be used in antibiotic development and treatment of drug-resistant strains.
    Polymyxin B2
  • HY-B0147A
    Pefloxacin mesylate 70458-95-6 99.73%
    Pefloxacin mesylate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse) Target: DNA gyrase Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections.
    Pefloxacin mesylate
  • HY-B0337A
    Sulfadimethoxine sodium 1037-50-9 99.76%
    Sulfadimethoxine sodium (Sulphadimethoxine sodium) is a sulfonamide antibiotic used to treat many infections.
    Sulfadimethoxine sodium
  • HY-B1149A
    Bacampicillin hydrochloride 37661-08-8 99.94%
    Bacampicillin hydrochloride is a penicillin antibiotic, is a prodrug of ampicillin with improved oral bioavailability.
    Bacampicillin hydrochloride
  • HY-B1794A
    Thiethylperazine dimaleate 1179-69-7 99.99%
    Thiethylperazine dimaleate, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine dimaleate is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine dimaleate has anti-emetic, antipsychotic and antimicrobial effects.
    Thiethylperazine dimaleate
Cat. No. Product Name / Synonyms Application Reactivity